Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance

G Capranico, R Supino, M Binaschi, L Capolongo, M Grandi, A Suarato and F Zunino

Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

To better define the role of the amino sugar in the pharmacological and biochemical properties of anthracyclines related to doxorubicin and daunorubicin, we have investigated the effects of various substituents at the 3'- and 4'-positions of the drug on cytotoxic activity and ability to stimulate DNA cleavage mediated by DNA topoisomerase II. The study shows that the nature of the substituent at the 3'-position but not the 4'-position is critical for drug ability to form cleavable complexes. The amino group at the 3'-position is not essential for cytotoxic and topoisomerase II-targeting activities, because it can be replaced by a hydroxyl group without reduction of activity. However, the presence of bulky substituents at this position (i.e., morpholinyl derivatives) totally inhibited the effects on the enzyme, thus supporting previous observations indicating that the cytotoxic potencies of these particular derivatives are not related to topoisomerase II inhibition. This conclusion is also supported by the observation that 3'-morpholinyl and 3'-methoxymorpholinyl derivatives are able to overcome atypical (i.e., topoisomerase II-mediated) multidrug resistance. Because a bulky substituent at the 4'-position did not reduce the ability to stimulate DNA cleavage, these results support a critical role of the 3'-position in the drug interaction with topoisomerase II in the ternary complex. An analysis of patterns of cross-resistance to the studied derivatives in resistant human tumor cell lines expressing different resistance mechanisms indicated that chemical modifications at the 3'-position of the sugar may have a relevant influence on the ability of the drugs to overcome specific mechanisms of resistance.

Volume 45, Issue 5, pp. 908-915, 05/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				W. Wu, Y. Luo, C. Sun, Y. Liu, P. Kuo, J. Varga, R. Xiang, R. Reisfeld, K. D. Janda, T. S. Edgington, et al. Targeting Cell-Impermeable Prodrug Activation to Tumor Microenvironment Eradicates Multiple Drug-Resistant Neoplasms Cancer Res., January 15, 2006; 66(2): 970 - 980. [Abstract] [Full Text] [PDF]

				A. V. Trevino, B. A. Woynarowska, T. S. Herman, W. Priebe, and J. M. Woynarowski Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues Mol. Cancer Ther., November 1, 2004; 3(11): 1403 - 1410. [Abstract] [Full Text] [PDF]

				A. Prinetti, L. Basso, V. Appierto, M. G. Villani, M. Valsecchi, N. Loberto, S. Prioni, V. Chigorno, E. Cavadini, F. Formelli, et al. Altered Sphingolipid Metabolism in N-(4-Hydroxyphenyl)- retinamide-resistant A2780 Human Ovarian Carcinoma Cells J. Biol. Chem., February 14, 2003; 278(8): 5574 - 5583. [Abstract] [Full Text] [PDF]

				F. Barcelo, D. Capo, and J. Portugal Thermodynamic characterization of the multivalent binding of chartreusin to DNA Nucleic Acids Res., October 15, 2002; 30(20): 4567 - 4573. [Abstract] [Full Text] [PDF]

				D. Schrijvers, A. M. E. Bos, J. Dyck, E. G. E. de Vries, J. Wanders, M. Roelvink, P. Fumoleau, S. Bortini, and J. B. Vermorken Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group Ann. Onc., March 1, 2002; 13(3): 385 - 391. [Abstract] [Full Text] [PDF]

				C. Geroni, M. Ripamonti, C. Arrigoni, F. Fiorentini, L. Capolongo, D. Moneta, S. Marchini, P. D. Torre, C. Albanese, M. G. Lamparelli, et al. Pharmacological and Toxicological Aspects of 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): A Novel Antineoplastic Agent Cancer Res., March 1, 2001; 61(5): 1983 - 1990. [Abstract] [Full Text]

				M. Binaschi, R. Farinosi, M. E. Borgnetto, and G. Capranico In Vivo Site Specificity and Human Isoenzyme Selectivity of Two Topoisomerase II-poisoning Anthracyclines Cancer Res., July 1, 2000; 60(14): 3770 - 3776. [Abstract] [Full Text]

				F. Guano, P. Pourquier, S. Tinelli, M. Binaschi, M. Bigioni, F. Animati, S. Manzini, F. Zunino, G. Kohlhagen, Y. Pommier, et al. Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines Mol. Pharmacol., July 1, 1999; 56(1): 77 - 84. [Abstract] [Full Text]

				C. Bailly, X. Qu, F. Anizon, M. Prudhomme, J.-F. Riou, and J. B. Chaires Enhanced Binding to DNA and Topoisomerase I Inhibition by an Analog of the Antitumor Antibiotic Rebeccamycin Containing an Amino Sugar Residue Mol. Pharmacol., February 1, 1999; 55(2): 377 - 385. [Abstract] [Full Text]

				M. Binaschi, G. Capranico, L. Dal Bo, and F. Zunino Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity Mol. Pharmacol., June 1, 1997; 51(6): 1053 - 1059. [Abstract] [Full Text]